Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Cell Division

Figure 1

From: FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients

Figure 1

Expression of FBXW 7 in glioma and correlation to survival. (A) FBXW 7 expression was measured by quantitative RT-PCR in 56 G-IV compared to a pool of 5 G-II. 73% of high grade tumors show very significant low levels of FBXW 7 transcripts (<0.5). (B) Relative levels of FBXW 7 were heterogeneous, but expression defines two groups of patients with different survival times after diagnosis. The median survival in the group with FBXW 7 levels >0.5 was 490 days, whereas patients with low expression (<0.5) had a median survival of 335 days. The difference between the two groups is significant (P = 0.0099, Mann-Whitney U-test, two-tailed). (C) Patients classified in the two groups as shown in B were subjected to Kaplan-Meier survival analysis. Survival curves for the two patient groups differed significantly (P = 0.011; Log-rank test). Note that two patients in the >0.5 group were still alive at the time the analysis were performed, more than 2000 days after initial diagnosis.

Back to article page